Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 14 and last traded at GBX 13.45, with a volume of 5803640 shares changing hands. The stock had previously closed at GBX 13.25.
Scancell Price Performance
The firm has a fifty day moving average of GBX 11.83 and a 200 day moving average of GBX 10.54. The company has a market capitalization of £139.58 million, a P/E ratio of -24.45 and a beta of 0.35. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79.
Scancell (LON:SCLP – Get Free Report) last posted its earnings results on Thursday, January 29th. The company reported GBX (0.55) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current year.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Gold $5,000: The 2026 Gold & Silver Summit is LIVE March 4
- How a Family Trust May Be Able To Help Preserve Your Wealth
- This makes me furious
- Elon Musk: This Could Turn $100 into $100,000
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
